The development of the Herceptest™ - From bench to bedside

Molecular Diagnostics: The Key Driver in Personalized Cancer Medicine

Volumn , Issue , 2010, Pages 43-60

  Jørgensen, Jan Trøst ^a   Winther, Henrik ^b  

^a Dx Rx Institute   (Denmark)

^b AGILENT TECHNOLOGIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84859210875     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4032/9789814241458     Document Type: Chapter

References (23)

1. Product approval information: letter to Genentech dated September 25, 1998, for Trastuzumab (Herceptin®). (http://www.fda.gov/Cder/foi/appletter/1998/trasgen092598l.pdf). Accessed July 2008.
2. Product approval information: letter to Dako dated September 25, 1998, for the DAKO HercepTest™. (http://www.fda.gov/cdrh/pdf/p980018.pdf). Accessed July 2008.
3. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature1986; 319: 226-230.
4. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 1986; 319: 230-235.
5. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire A. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
6. Slamon D, Pegram M. Rationale for Trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol 2001; 28 (Suppl 3): 13-19.
7. Hortobagyi GN. Opportunities and challenges in the development of targeted therapies. Semin Oncol 2004; 31 (Suppl 3): 21-27.
8. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
9. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu, E, Martino S, Soonmyung P, Kaufmann PA et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positve breast cancer. N Engl J Med 2005; 353: 1673-84.
10. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C et al. Trastuzumab after adjuvant chemotherapy in HER2-positve breast cancer. N Engl J Med 2005; 353: 1659-72.
11. Baselga J, Perez EA, Pienkowski T, Bell R. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. Oncologist 2006; 11 (Suppl 1): 4-12.
12. HercepTest™, Package Insert, Dako. (http://www.dakousa.com/prod_downloadpackageinsert.pdf?objectid=11497200 2). Accessed July 2008.
13. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-712.
14. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-145.
15. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM et al. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med 2007; 131(1): 18.
16. Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 2004; 10: 6759-6763.
17. Drug-Diagnostic Co-Development Concept Paper. Draft. Food and Drug Administration (FDA) April 2005. (http://www.fda.gov/cder/genomics/pharmacoconceptfn.pdf). Accessed August 2008.
18. Jørgensen JT, Nielsen KV, Ejlertsen B. Pharmacodiagnostics and targeted therapies - A rational approach for individualizing medical anti-cancer therapy in breast cancer. Oncologist 2007; 12: 397-405.
19. Ellis IO, Dowsett M, Bartlett J, Walker R, Cooke T, Gullick W, Gusterson B, Mallon E, Lee PB. Recommendations for HER2 testing in the UK. J Clin Pathol 2000; 53: 890-2.
20. Dybdal N, Leiberman G, Anderson S, McCune B, Bajamonde A, Cohen RL, Mass RD, Sanders C, Press MF. Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab. Breast Cancer Res Treat 2005; 93: 3-11.
21. Nordic immunohistochemical Quality Control (http://www.nordiqc.org). Accessed October 2008.
22. United Kingdom National External Quality Assessment Service. (http://www.ukneqas.org.uk/content/Pageserver.asp). Accessed October 2008.
23. Dowsett M, Hanna WM, Kockx M, Penault-Llorca F, Rüschoff J, Gutjahr T, Habben K, van de Vijver MJ. Standardization on HER2 testing: Results of an international proficiency-testing ring study. Mod Pathol 2007; 20: 584-591.